The PEERLESS Study
Completed · Not applicable · NCT05111613
Conditions: Pulmonary Embolism, Pulmonary Thromboembolism
At a glance
- Research payments reported, 2025
- $31,433
- U.S. investigators named
- 5
- Sites paid
- 1
- Planned or actual enrollment
- 692
About the trial
- Sponsor
- Inari Medical
- Tested
- Catheter-Directed Thrombolysis (device), FlowTriever System (device)
- Dates
- Started 2022-02-14; completion 2024-04-11
- Results posted
- Yes
A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.
From ClinicalTrials.gov, last updated 2025-11-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Stryker Corporation reported $31,433 in research payments for this study in 2025 (8 payments).
Products named: Flowtriever Catheter, S
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Bhavraj Khalsa, M.D. Interventional Radiology · Orange, CA
- Samy Selim, MD Internal Medicine · Manhasset, NY
- Carin F. Gonsalves, M.D. Interventional Radiology · Philadelphia, PA
- Parth M. Rali, MD Pulmonology · Philadelphia, PA
- David J. Dexter II, MD Vascular Surgery · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $25,433
- Sentara Vascular Specialists $6,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.